AEMD - Aethlon Medical, Inc.
| Previous Close | 1.06 |
| Open | 1.06 |
| Bid | 0.00 x 2200 |
| Ask | 1.35 x 800 |
| Day's Range | 1.06 - 1.20 |
| 52 Week Range | 0.79 - 2.04 |
| Volume | 180,021 |
| Avg. Volume | 89,751 |
| Market Cap | 21.18M |
| Beta | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- PR Newswire•3 days ago
Aethlon Medical Receives National Cancer Institute Award
The Aethlon Hemopurifier is a first-in-class therapeutic technology designed for the rapid depletion of circulating viruses and cancer promoting exosomes. The FDA has designated the Hemopurifier as a "Breakthrough Device" for the treatment of life-threatening viruses for which there are no approved therapies.
- Zacks Small Cap Research•24 days ago
AEMD: Compassionate Use, Real-World Data, Awaiting FDA Final Guidance
Revenue of $150k represented the final payment from the phase I NCI cancer grant. A subsequent, phase 2 contract worth approximately $1.5M over two years, could follow – AEMD’s application for which is expected to be submitted later this year. Updates to several of the development programs were provided on the call, including that related to Hemopurifier under the Breakthrough Device designation, Hemopurifier’s potential role in cancer therapy and updates in the ESI segment – including CTE/TauSome study enrollment status and potential new opportunities.
- GlobeNewswire•25 days ago
Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball ...
- PR Newswire•last month
Aethlon Medical Announces First Quarter Fiscal Year 2019 Results
SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- ACCESSWIRE•last month
Aethlon Medical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...
- PR Newswire•2 months ago
Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018
SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...
- Simply Wall St.•3 months ago
Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven
Aethlon Medical Inc’s (NASDAQ:AEMD): Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. On 31 March 2018, theRead More...
- PR Newswire•3 months ago
Guy Cipriani Joins Aethlon Medical's Board of Directors
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules. Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries.
- Zacks Small Cap Research•3 months ago
AEMD: AEMD In Active Discussions With FDA Regarding Hemopurifier Pathway
Revenue of $75k, which was largely inline with our $89k estimate, relates entirely to a second milestone from the NCI cancer grant. Subsequent to the close of fiscal 2018, AEMD billed an additional $112k for work completed under this grant.
- PR Newswire•3 months ago
Aethlon Medical Announces Fiscal 2018 Results
SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- PR Newswire•4 months ago
Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018
Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...
- Simply Wall St.•4 months ago
Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- ACCESSWIRE•5 months ago
GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...
- PR Newswire•6 months ago
Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix
PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics, for biomarker discovery projects. With the approval of the protocol, investigators plan to initiate screening of candidate participants in the coming weeks. The study will enroll former NFL players, who are at high-risk of suffering from CTE, and control subjects who didn't participate in activities that involved repetitive head trauma.
- PR Newswire•7 months ago
Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting
SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting. The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th. The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/presentations. The American Society for Microbiology Biothreats Meeting is being held today, February 12th through the 14th at the Hilton, Baltimore Md. The event includes tracks on high consequence pathogen research, biological threat reduction, product development, and policy.
- Zacks Small Cap Research•7 months ago
AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset
By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...
- PR Newswire•8 months ago
Aethlon Medical Announces Fiscal 2018 Third Quarter Results
SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- PR Newswire•8 months ago
Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018
SAN DIEGO , Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third ...
- PR Newswire•8 months ago
Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes
SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that validation has completed and the opposition period expired for European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great Britain, and Spain. In recent years, exosomes have emerged as a significant diagnostic and therapeutic tool for a wide range of disease conditions, including cancer, tuberculosis, Alzheimer's, and chronic traumatic encephalopathy (CTE).
- Simply Wall St.•8 months ago
Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?
Aethlon Medical Inc (NASDAQ:AEMD), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered, smallRead More...
- PR Newswire•8 months ago
Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections
SAN DIEGO, Jan. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418 Application"), entitled "METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients. The '418 Application is a continuation of U.S. Patent Number 7,226,429, which embodies methods of reducing viral loads in the blood of individuals infected with a virus. Together, this intellectual property further protects the Aethlon Hemopurifier® and secures Aethlon's position as a leader in pioneering therapeutic strategies to address viral infections.
